Compare SPRO & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | NVX |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | United States | Australia |
| Employees | N/A | 192 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 146.4M |
| IPO Year | 2017 | N/A |
| Metric | SPRO | NVX |
|---|---|---|
| Price | $2.24 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 261.3K | ★ 404.4K |
| Earning Date | 03-26-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | $3,904.19 |
| Revenue Next Year | N/A | $91.72 |
| P/E Ratio | $15.53 | ★ N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $0.51 | $0.63 |
| 52 Week High | $3.09 | $3.86 |
| Indicator | SPRO | NVX |
|---|---|---|
| Relative Strength Index (RSI) | 39.83 | 35.65 |
| Support Level | $2.15 | $0.63 |
| Resistance Level | $2.44 | $1.02 |
| Average True Range (ATR) | 0.13 | 0.05 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 4.35 | 8.22 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
NOVONIX Ltd is a battery technology company developing and scaling materials and equipment critical to the lithium-ion battery supply chain. The company has three operating segments: Battery Materials: It develops and manufactures battery anode materials, ii) Battery Technology: It develops and manufactures battery cell testing equipment, performs consulting services and carries out research and development in battery development, and Graphite Exploration: It manages the maintenance and future development of Mount Dromedary natural graphite deposit. The majority of the company's revenue is derived from the Battery Technology segment. Geographically, the maximum revenue is derived from North America, followed by Asia, and Europe.